A
Alasdair Coles
Researcher at University of Cambridge
Publications - 244
Citations - 12484
Alasdair Coles is an academic researcher from University of Cambridge. The author has contributed to research in topics: Alemtuzumab & Multiple sclerosis. The author has an hindex of 45, co-authored 233 publications receiving 10742 citations. Previous affiliations of Alasdair Coles include University Hospital of Wales & University College London.
Papers
More filters
Journal ArticleDOI
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A. Cohen,Alasdair Coles,Douglas L. Arnold,Christian Confavreux,Edward Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Elizabeth Fisher,Vesna V. Brinar,Gavin Giovannoni,Miroslav Stojanovic,Bella Ertik,Stephen Lake,David Margolin,Michael Panzara,D Alastair S Compston +17 more
TL;DR: Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit interms of disability endpoints noted in previous trials was not observed here.
Journal ArticleDOI
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial
Alasdair Coles,Cary Twyman,Douglas L. Arnold,Jeffrey A. Cohen,Christian Confavreux,Edward Fox,Hans Peter Hartung,Eva Havrdova,Krzysztof Selmaj,Howard L. Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Rupert Sandbrink,Stephen Lake,David Margolin,Pedro Oyuela,Michael Panzara,D Alastair S Compston +18 more
TL;DR: This 2 year, rater-masked, randomised controlled phase 3 trial enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer and found alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability.
Journal ArticleDOI
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
Camms Investigators,Alasdair Coles,D Alastair S Compston,Krzysztof Selmaj,Stephen Lake,Susan Moran,David Margolin,Kim Norris,P K Tandon +8 more
TL;DR: In patients with early, relapsing-remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura.
Journal ArticleDOI
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.
Alasdair Coles,M. G. Wing,Paul Molyneux,Andrea Paolillo,Charlie M. Davie,Geoff Hale,David Miller,H Waldmann,Alastair Compston +8 more
TL;DR: Evidence is provided supporting the emerging view that treatment in multiple sclerosis must be given early in the course, before the consequences of inflammation are irretrievably established, and the formulation that inflammation and demyelination are responsible for relapses of multiple sclerosis is supported.
Journal ArticleDOI
The window of therapeutic opportunity in multiple sclerosis : Evidence from monoclonal antibody therapy
Alasdair Coles,Amanda L. Cox,E. Le Page,Joanne L. Jones,S. A. Trip,J. Deans,S. R. Seaman,David Miller,Geoff Hale,Herman Waldmann,D. A. S. Compston +10 more
TL;DR: It is speculated that the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long–term axonal degeneration, are currently being tested in a controlled trial comparing Campath–1H and IFN–beta in the treatment of drug–naïve patients with early, active RR MS.